The arrival of Pfizer’s blue pill Sildenafil in 1998 brought a great relief both to patient and physician signalling the start of a great era of medical therapy in sexual medicine. Since then the sexual medicine experts have been prescribing sildenafil in erectile dysfunction with acceptable minor adverse events. But the use of sildenafil in premature ejaculation (PE) is still debated. 2018 being the 20th anniversary of sildenafil, we have compiled interesting facts about the role of sildenafil in PE from various original articles, systematic reviews, meta-analyses, economic brochures and sexual medicine committee guidelines. The major issues in most of these studies were the heterogeneity in the definition of PE and estimating the exact ejaculatory latency time. This perspective article highlights the positive role of sildenafil in the management of PE (even without ED) with acceptable adverse events. Now that we have a standardised definition of PE from International Society of Sexual Medicine (ISSM) and a psychogenic component in PE definition, more randomised placebo-controlled studies are required to further establish its role.

辉瑞公司的蓝色药片西地那非（Sildenafil）于1998年问世，这给患者和医生带来了极大的慰藉，标志着性医学医学治疗时代的开始。从那以后，性医学专家一直在处方西地那非治疗勃起功能障碍，并伴有轻微的不良反应。但是西地那非在早泄（PE）中的使用仍存在争议。2018年是西地那非20周年，我们从各种原始文章，系统评价，荟萃分析，经济手册和性医学委员会指南中收集了有关西地那非在PE中的作用的有趣事实。这些研究大多数的主要问题是PE定义的异质性和估计射​​精潜伏期的确切时间。这篇观点文章强调了西地那非在具有可接受不良事件的PE（即使没有ED）的管理中的积极作用。既然我们已经有了国际性医学协会（ISSM）对PE的标准化定义，并且在PE定义中加入了心理因素，则需要进行更多随机安慰剂对照研究才能进一步确定其作用。